secwatch / observer
8-K filed November 10, 2022, 6:59 PM ET CIK 0000008868
other material confidence high sentiment negative materiality 0.70

AVON PRODUCTS INC: restructuring charge — Avon Products approves closure of Suffern R&D facility, relocation to Brazil and Poland with $39M restructuring costs

AVON PRODUCTS INC

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.7

AVON PRODUCTS INC announced a impairment with charges of $35.0 million to $40.0 million affecting fixed assets related to Suffern facility closure.

Type
impairment
Charge
$35.0 million to $40.0 million
Affected area
fixed assets related to Suffern facility closure
Exact text from the filing
Avon is also performing an impairment analysis over fixed assets and, as a result, expects to record a potential impairment charge in the range of $35.0 million to $40.0 million.
View on SEC.gov
Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

AVON PRODUCTS INC announced a restructuring with charges of approximately $39.0 million affecting research and development facilities in Suffern, New York, relocated to Brazil and Poland.

Type
restructuring
Charge
approximately $39.0 million
Affected area
research and development facilities in Suffern, New York, relocated to Brazil and Poland
Exact text from the filing
development activities to Brazil and Poland. Avon expects to incur non-recurring restructuring costs in connection with the closure and relocation in the amount of approximately $39.0 million, to be incurred in the fiscal years ending December 31, 2022, 2023, 2024 and 2025 and capital expenditures relating to the infrastructure and facilities in Brazil and Poland
View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR
accession 0000950103-22-019486
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.